Dual engine assist! Yonglirong’s first-quarter revenue reached 26.7 million yuan, a new high for the same period
Yonglirong (6973)’s consolidated revenue in March reached 10.56 million yuan, a monthly increase of 30.43% and an annual increase of 24.25%; the cumulative first quarter consolidated revenue reached 26.7 million yuan, an annual increase of 33.44%, setting a new high for the same period in the past, showing that the company’s layout in the health care and skin care products market is gradually fermenting.
Benefiting from the series of skin care products using exosomes extracted from deer amniotic fluid, market attention and consumer acceptance have rapidly increased, and the channel sales have been significantly enhanced. At the same time, deer antler active polypeptide-related health products have achieved outstanding sales performance and booming shipments since their launch. The dual engines have boosted Yongliron’s first-quarter revenue and achieved brilliant results.
Yong Lirong pointed out that the company has successfully transformed the research and development experience of UA002, a new drug for the treatment of male erectile dysfunction (ED), into the logic of health food development, launching “ACT-A Black Deer Supergene Capsules”, which combines the patented velvet antler peptide ACT-A with organic maca to target the male functional health care market and seize the global male erectile dysfunction extended market opportunity of more than 300 billion yuan.
Looking forward to 2026, Evergreen maintains a cautiously optimistic view. In the future, it will continue to integrate deer amniotic fluid stem cells and exosomes, deer umbilical cord stem cells and exosomes, and deer antler active peptides through the i-ExoCraft platform, deepen its own brand and ODM/OEM business, and expand the layout of high value-added products.
In addition, the company will target the male high-frequency consumer market and work with brand partners to develop a series of new products covering male function, physical conditioning and daily maintenance. Among them, a new wave of male function products are expected to be launched in the second half of the year, which is expected to continue the channel’s strong momentum of attracting goods and promote continued growth in the annual operating scale.
In terms of new drug research and development, Yongliron is simultaneously advancing its regenerative medicine layout. Its new amniotic fluid stem cell drug UA002 has entered Phase II clinical trials, and its new dry eye disease drug UB003 is also steadily advancing follow-up clinical planning. In the future, we will continue to focus on the fields of neurological, aging and inflammation-related diseases, and use the technical advantages accumulated in new drug research and development to feed back into the development of health and maintenance products, forming a business model of “technology platform sharing, product matrix expansion” to strengthen the company’s competitiveness in the regenerative medicine and general health markets.